IDDF2026-ABS-0193 Development and validation of GI symptoms animated pictograms (GAPs) as a diagnostic tool for gi dysfunction among patients with cognitive impairment

Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

IRRITABLE BOWEL SYNDROME IS ASSOCIATED WITH A 2.5-FOLD INCREASED RISK OF INFERTILITY AMONG PRIMARY CARE PATIENTS

Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS

A comparison of diagnostic methodologies for small intestinal bacterial overgrowth: aspirate culture, breath testing and the Atmo capsule

Tu1669 CHRONIC GASTROINTESTINAL SYMPTOMS AND SYSTEMIC COMORBIDITIES IN ADULT PATIENTS WITH HYPERMOBILITY SPECTRUM DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP

Advancing hepatitis C elimination in prisons: a state-specific modelling study of integrated harm-reduction and addiction interventions

Prevalence of orthostatic intolerance in patients with disorders of gut-brain interaction: a systematic review and meta-analysis

Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL

SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/ 2 DOSE ESCALATION AND OPTIMIZATION TRIAL

Acute effects of botulinum toxin on the distensibility of the LES in patients with suspected achalasia and esophageal outlet obstruction

Addiction medicine involvement is associated with improved hepatitis C and viral hepatitis screening among hospitalised incarcerated patients who inject drugs

582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

WEIGHT LOSS OUTCOMES IN RESPONSE TO TREATMENT WITH DUODENAL-JEJUNAL BYPASS LINER ARE THE SAME REGARDLESS OF DIABETES SEVERITY ASSESSED USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE

Results From Dose Escalation Cohorts 1-6 of RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) for Eosinophilic Esophagitis

Updated dose escalation results from RESOLVE, an ongoing Phase 1b/2a study of EP-104GI (long-acting fluticasone propionate injectable suspension) for eosinophilic esophagitis